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Abstract
Background: In Canada – a low endemicity country, vaccines for hepatitis A virus (HAV) are currently recommended
to individuals at increased risk for infection or its complications. Applying these recommendations is difficult because the
epidemiology of HAV infection is poorly defined, complex, and changing. This systematic review aimed to 1) estimate
age-specific prevalence of HAV antibody in Canada and 2) evaluate infection-associated risk factors.
Methods:  MEDLINE (1966–2005) and EMBASE (1980–2005) were searched to identify relevant studies for the
systematic review. Archives for the Canada Diseases Weekly Report (1975–1991) and Canada Communicable Disease
Report (1992–2005) were searched for relevant public health reports. Data were abstracted for study and participants'
characteristics, age-specific prevalence, and risk factors.
Results: A total of 36 reports describing 34 unique studies were included.
The seroprevalence in Canadian-born children was approximately 1% in ages 8–13, 1–6% in 20–24, 10% in 25–29, 17%
in 30–39, and increased subsequently. In age groups below 20 and 20–29, age-specific seroprevalence generally remained
constant for studies conducted across geographic areas and over time.
Compared to Canadian-born individuals, subjects born outside Canada were approximately 6 times more likely to be
seropositive (relative risk: 5.7 [95% CI 3.6, 9.0]). Travel to high risk areas in individuals aged 20–39 was associated with
a significant increase in anti-HAV seropositivity (RR 2.8 [1.4, 5.5]). Compared to heterosexuals, men having sex with men
were only at a marginally higher risk (adjusted odds ratio 2.4 [0.9, 6.1]). High risk for seropositivity was also observed
for Canadian First Nations and Inuit populations.
Conclusion: Results from the current systematic review show that in this low endemicity country, disease acquisition
occurs in adulthood rather than childhood. The burden of disease is high; approximately 1 in 10 Canadians had been
infected by ages 24–29. The increase in prevalence in young adults coincides with disease importation and increasing
frequency of risk factors, most likely behavioral-related ones.
Gaps in seroprevalence data were identified rendering the application of current immunization recommendations 
difficult. A nationwide prevalence survey for all Canadians is needed. This is essential to quantify the effectiveness of 
current recommendations and conduct cost-effectiveness evaluations of alternative immunization programs, if necessary.
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Background
Hepatitis A virus (HAV) is prominent in many areas of the
world [1-3]. In North America, infection rates have
declined with better hygiene practice and public sanita-
tion but remain heterogeneous across geographic and
socioeconomic strata [4-6]. Further decline is possible
with HAV vaccines which provide consistent, long-lasting
protection and have been available since the mid-1990s
[7,8]. In the United States, universal vaccination of chil-
dren and youth has been in place for about 6 years in high
endemicity areas [9], leading to historically low rates
nationally in recent years [10]. In Canada, the current
national immunization guide recommends HAV vaccines
for individuals at increased risk of infection or its compli-
cations. The guide also states that a universal immuniza-
tion program should be considered, but further
discussion is needed nationally [11].
Applying the Canadian recommendations is difficult
because the epidemiology of HAV infection in Canada is
poorly defined, complex, and changing [8]. Reported rates
differ substantially by province, gender, and age [12]. The
rates show repeated peaks and troughs [13] and the last
peak occurred in mid-1990 [12,13]. It was during the sub-
sequent period of decline that vaccines were used as a tool
to enhance HAV control [8].
Evaluating the impact of the current recommendations is
also difficult. Data are needed to distinguish between a
cyclical decline and a further decline associated with the
recommendations [10]. Such assessment is important to
inform future immunization policies. A combination of
timely case-notification data, prevalence data, and risk
factor data is required for both the application and evalu-
ation of the recommendations.
Case-notification data is of limited use due to under-
detection of sub-clinical infection and under-reporting of
confirmed cases [8,14]. A useful means that circumvent
these limitations is to measure the prevalence of HAV
antibody [15]. Following an acute infection, antibody to
HAV develops in virtually every instance, remaining
detectable for decades, and providing a reliable marker of
past infection. In the United States, countrywide seroprev-
alence surveys and sentinel surveillance have been con-
ducted to provide insight into HA epidemiology, and to
rationalize and evaluate immunization programs
[10,15,16]. In Canada, similar surveys exist but are lim-
ited in scope and comprehensiveness [17-19]. Conse-
quently, risk factor data are also limited and fragmented
[12,17]. The current systematic review aimed to 1) esti-
mate age-specific prevalence of hepatitis A antibody in
Canada and 2) evaluate infection-associated risk factors.
Methods
MEDLINE (Jan. 1966 – Mar. 2005) and EMBASE
(Jan.1980 – Mar. 2005) were searched to identify citations
of potentially relevant studies for the systematic review
(MeSH terms: "hepatitis" exploded AND "Canada"
exploded). A study report was included if it contained
prevalence data of HAV-antibody (detected through sera
or saliva samples, hereafter referred to as seroprevalence)
for a Canadian population. Reasons for exclusion were
categorized and reported. Citations were screened inde-
pendently by two reviewers. Full-text study reports from
citations deemed relevant by one reviewer were obtained.
Archives for the Canada Diseases Weekly Report (Jan.
1975 – Dec. 1991, the last year of reporting) and Canada
Communicable Disease Report (Jan. 1992 – Mar. 2005)
were also searched for potentially relevant public health
reports [20]. Two reviewers independently reviewed both
published and public health reports. Discrepancies were
resolved through discussion. Back referencing and author
searches of all included studies were conducted. Other
potentially relevant reports were obtained by contacting
HA experts and related public health units.
From the included reports, data were independently
abstracted for study and participants' characteristics. Age-
specific prevalence of HAV antibody data were extracted
for Canadian-born participants, all Canadians including
individuals born outside the country, and participants
with known risk factors [11]. Seroprevalence estimates
and 95% confidence intervals (CI) were derived assuming
a binomial distribution for the number of seropositive
individuals from the total numbers of tested individuals.
Participants who reported receiving the HA vaccine were
excluded from the prevalence estimates as they were likely
to have vaccine-induced antibody.
If available, adjusted odds ratios (AOR) for seropositivity
of both demographics and risk factors were extracted,
together with the baseline risk of HAV seropositivity (i.e.,
population, location and timing of the survey). When the
AOR of a variable was not reported, HAV antibody data
stratified by the variable were obtained to derive the unad-
justed relative risk for seropositivity (URR). Relative risk
was used as it is a better risk estimate than the odds-ratio
in the range of seroprevalence observed in this systematic
review [21]. If appropriate, a random effects model was
used to combine URRs across studies, together with an
assessment for heterogeneity (i.e., chi-squared test).
Information related to the risk of seropositivity was sum-
marized for the following risk categories [11]: 1) travelers
to high endemicity areas; 2) groups with high risk activi-
ties such as men who have sex with men (MSM), illicit
drug users, and street people; 3) First Nations and Inuit
populations; and 4) others (e.g., individuals with chronicBMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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Table 1: Study and participant characteristics
Study Study 
Design
Study Year n Population Location Age in years
PUBLISHED 
LITERATURE
Mean ± SD or 
(range)
Ochnio 2005* [22] P 2000–1 811 Grade 9 students British Columbia (14–15)
Muecke 2004* [23] CC 2001 492 Day-care educators Montreal 37
Minuk 2003 [24] P 1999 315 First Nations Manitoba 34 ± 15
Ochnio 2001 [25] P 1998 494 Street youth, IDU, MSM Vancouver 19, 35, 34
Smieja 2001 [26] CC 1997–8 179 IHD patients Hamilton 61 (38–81)
Kiefer 2000 [27] R 1997 343 Hepatitis C patients Edmonton 40 (0–95)
Allard 2001 [28] P 1995–97 353 Gay men Montreal 37
Moses 2002 [29] P 1995–6 533 Street people Winnipeg 26 (11–65)
Roy 2002 [30] R 1995–6 427 Street youth Montreal (14–25)
Ochnio 1997 [31] P 1995–6 224 Grade 6 students Vancouver (10–12)
De Serres 1997 [32] P 1995 85 Sewer workers Quebec 36 ± 7
De Serres 1995 [33] CC 1995 228 Sewer workers Quebec 41 (28–64)
Smieja 2003 [34] R 1993–5 3127 CV or high risk diabetes Canada 65
Payment 1991 [18] P 1988–9 617 French-Canadian Montreal (9–79)
Embil 1989 [35] P 1981–3 2036
1922
1/CF recruits
2/CF males
Nova Scotia, 
Quebec, Posted 
abroad
1/(15–25)
2/26 (17–53)
Nicolle 1986 [36], Minuk 
1985 [37]
P 1982 172 Chesterfield Inlet Northwest 
Territories
0 – 78
Crewe 1983 [38] P 1981–2 304 Children attending outpatient clinic Halifax (0.5–16)
Minuk 1982 [39]
Minuk 1982 [40]
P 1980 720 Inuit Northwest 
Territories
(0.3–86)
McFarlane 1980 [41] P, R 1980 243
152
293 & 282
1/STD clinic patients
2/Student nurses
3/2 groups of blood donors
Nova Scotia 1/(16–26)
2/(18–24)
3/(16–26) & 
(51–65)
Buchner 1980 [42] R 1980 5097 Blood donors Toronto <21, >60
Richer 1982 [55] R 1970–79 447 Samples of acute viral hepatitis Montreal Not reported
Minuk 1994 [43] P 1974–8 42 Household transmission Winnipeg 27 ± 12
Minuk 2003 [44] SR 1980–2000 1706 Inuit and First Nations Various locations 0–60+
McFarlane 1982 [45] P NR 154 Institutions Nova Scotia (13–28)
McFarlane 1981 [46] P NR 130 Patients with hematological 
malignancy
Nova Scotia (4–76)
GREY LITERATURE
Duval 2005* [48] P 2003 1057 Canadian aged 8–13 Canada (8–13)
Wu 2005 [47] R 1992–9 NR Subjects tested for HAV infection Manitoba Not reported
Ochnio 2004 [49] P 2003 585 Young adults Vancouver (20–39)
Cook 2000 [19] R 2000 1206 Women of child-bearing age British Columbia (15–44)
Harb 2000 [50] P 1999 172 First Nations British Columbia (0–40+)
Levy 2001 [51] P 1997 1000 University students Toronto 25 ± 5
Ford-Jones 1995 [52] P 1993 122 Day-care providers Toronto Not reported
Ochnio 1995 [53] P 1994–5 1019 Clients to travel clinic Vancouver (2–69+)
Kocuipchyk 1995 [54] P 1991–2 505 Individuals attending travel clinic Edmonton (16–60+)
Notes:*Study reported seroprevalence data for individuals with or without HAV vaccination.
Abbreviations: Study design: P prospective data acquisition, R retrospective data acquisition, CC case control, SR systematic review. Population: 
IDU injection drug users, MSM men who have sex with men, IHD ischemic heart disease, CV cardiovascular, CF Canadian Forces, STD sexually 
transmitted disease.BMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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hepatitis, household contacts, infected food handlers,
etc.).
Results
Literature search
A total of 36 reports describing 34 unique studies were
included in the systematic review (Table 1) [18,19,22-55].
These were obtained from screening 413 potentially rele-
vant citations and reviewing 66 full-text study reports and
25 public health reports (Figure 1). Common reasons for
exclusion at the screening stage included studies of hepa-
titis B virus (n = 95), hepatitis C virus (n = 64), commen-
taries (n = 24), and others (n = 121; Figure 1). Common
reasons for exclusion at the full-text review stage included
general review of HAV (n = 9), no seroprevalence data (n
= 17), and other viral hepatitis (n = 16; Figure 1).
Overall, 74% (n = 25) of the included studies were
reported in peer-reviewed journals while 26% (n = 9)
were grey literature [20], including 9% (n = 3) public
health reports, 14% (n = 5) abstracts, and 3% (n = 1)
unpublished study (Table 2). HAV antibody was detected
using serum samples in 28 studies and saliva samples in
6. The median sample size was 427 and 793 for the pub-
lished and grey literature studies, respectively. Only 21%
(7/34) of all studies reported prevalence among Cana-
dian-born participants and 29% (10/34) reported preva-
lence data of all participants including foreign-born
individuals. The majority of these studies (27/34)
reported prevalence data of participants with known risk
factors.
Age-specific seroprevalence
The seroprevalence in Canadian-born children aged 8–13
was 1% [95% CI: 0.5–2%] according to a national survey
conducted in 2003 [48]. The seroprevalence was 1–6% in
ages 20–24, approximately 10% in 25–29, 17% in 30–39,
and increased subsequently (Figure 2). In age groups
below 20 and 20–29, age-specific seroprevalence gener-
ally remained constant for studies conducted across geo-
graphic areas in 1980, 1988, 1997, and 2003. This
remained so despite differences in study methodology.
There was no association between seropositivity and gen-
der based on 9 population comparisons from 5 studies (n
= 4158, URR: 1.0 [95% CI: 0.9, 1.1]) [22,31,35,41,54],
which was consistent with results of 3 other studies
reporting adjusted risk estimates (Table 3) [25,34,48].
Two studies in the early 1980's suggested that individuals
living in urban areas were 30% more likely to have HAV
antibody compared to those in rural areas (n = 647, URR:
1.3 [1.2, 1.5]) [41,46].
Compared to Canadian-born individuals, subjects born
outside Canada were approximately 6 times more likely to
be seropositive (n = 3008, URR: 5.7 [3.6, 9.0], Table 3)
[30,31,49,51,53], which most likely occurred in their
birth country. However, the possibility that infection
occurred in Canada could not be ruled out. Age-specific
seroprevalence estimates including these individuals var-
ied substantially and could only be used to infer the level
of immunity in the population. For example, seropreva-
lence among all Canadians aged <20 ranged from 2–16%
[18,31,38,48,51] for which 3–25% of the sampled popu-
lations were individuals born outside the country
Results of the literature search Figure 1
Results of the literature search.
Citations from Medline & EMBASE Searches n=413
Full text articles retrieved n=66
Public health (PH) reports obtained by
contacting PH departments n=25
Citations excluded n=347
Reasons: HBV n=95; HCV n=64; HDV n=3;
HEV n=6; HGV n=2; HBV/HCV n=18;
Animal study n=14; Commentary n=24; Other n=121
Articles excluded n=47
Reasons: HAV articles: Review n=9, Guides n=5,
No seroprevalence data n=17;
Other viral hepatitis n = 16
Public health reports excluded n=23
Reasons: HAV incidence data only n=21;
Other viral hepatitis n=2
Relevant articles n = 19
Relevant PH reports n = 2
Relevant articles through expert contact n = 4
Relevant articles through back referencing
& author searches n = 11
Included study reports n = 36BMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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[25,48,53]. This contrasted the 1% seropositivity for
Canadian-born participants reported above.
Risk factors
Travel-related data were available in 6 studies (Table 1)
[23,35,48,49,53,54]. HAV antibody prevalence for
Canadian-born individuals visiting a travel clinic was
2.3% in ages 20–25 and 4.3% in ages 25–28 [53]. The
prevalence of seropositivity in these individuals was com-
parable to that reported above for Canadian-born individ-
uals. The risk related to travel among Canadian-born was
also not significant in a study of day-care educators [23].
Two population-based surveys reported travel-related risk
[48,49]. In one study, travel to high risk areas by Cana-
dian-born individuals aged 20–39 (approximately 12% of
study participants) was associated with a significant
increase in seropositivity (n = 407, URR: 2.8 [1.4, 5.5])
[49]. In a national survey of children aged 8–13, the prev-
alence was 1.9% in Canadian-born non-vaccinated trave-
lers and 1.3% in non-travelers; the association was again
not significant (Table 3) [48].
Two studies evaluated HAV infection among MSM in two
different cities [25,28]. MSM participants on average had
3 sexual partners over the preceding 6 months, according
to one study [28]. Also, 18% of these individuals were
food handlers. Compared to heterosexuals, MSM were
only at a marginally higher risk for seropositivity (n = 494,
AOR 2.4 [0.9, 6.1]), according to the second study [25].
However, the study sample was highly heterogeneous and
included MSM, injection drug users (IDU), and street
youth.
Data on street-involved populations were available in
three studies (Table 3) [25,29,30]. Seropositivity was
approximately 5% in street youth aged 14–25 in Vancou-
Table 2: Study characteristics
Published Literature (n = 25) Grey Literature (n = 9)
Peer-reviewed study report (n = 25) Public health report (n = 3)
Abstract (n = 5)
Unpublished report (n = 1)
Study Design
Case-control 2 0
Prospective (P) data acquisition 16 7
Retrospective (R) data acquisition 5 2
P & R data acquisition 1 0
Systematic review 1 0
Sample Size
>1000 4 3
100 – 1000 19 6
<100 2 0
Median [1st, 3rd Quartile] 427 [224, 720] 793 [422, 1029]
Mean (Min, Max) 877 (42, 5097) 708 (122, 1206)
Timing of data collection
2000 – 2004 2 3
1990 – 1999 12 6
1980 – 1989 7 0
1970 – 1979 2 0
Not reported 2 0
Populations with prevalence data
Canadian born subjects 4 3
All Canadians¶ 6 4
Participants with known risk factors 21 7
Seropositivity test
Serum samples 22 6
Saliva samples 3 3
Notes: ¶including subjects born outside of CanadaBMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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ver and Montreal [25,30]. In the Montreal study [30], the
outbreak in MSM (n = 376 cases from December 1994 to
February 1998 [28]) seemed to have little effect on the
prevalence of anti-HAV among street youth, measured
during the same period. Significant behavioral risk factors
for seropositivity were reported for street-involved indi-
viduals. These included IDU, history of sexually-transmit-
ted disease, and high HAV-risk sexual activities (Table 3).
Seroprevalence in Canadian First Nations and Inuit popu-
lations were reported in four studies and summarized in a
systematic review [44]. The prevalence ranged from 75–
95% and was approximately three times that of non-Abo-
riginal Canadians residing in the same communities
across all ages [44]. For example, Minuk and colleagues
reported on a seroprevalence survey of 720 inhabitants of
an Inuit community (n = 850). Approximately 27% of this
community were aged 0–9, 30% aged 10–19, 32% aged
20–49, and 11% aged 50 or above [40].
Among Canadian-born day-care educators, there was a
borderline significant association between risk of HAV
positivity and years of employment (Table 3) [23]. A his-
tory of daycare attendance among grade 6 students was
Seropositivity rate (95% confidence interval) among Canadian-born study participants Figure 2
Seropositivity rate (95% confidence interval) among Canadian-born study participants.BMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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Table 3: Assessment of risk factors
Risk factor n Risk 
Measure
Risk 
Estimate 
(95% CI)
Population, Location, Timing 
of Data Acquisition
Age in 
years
Study
DEMOGRAPHICS Mean ± SD 
or (range)
Female versus Male 1003 AOR 2.2 (0.8, 6.25) School-aged children, Canada, 
2003
(8–13) [48]
Female versus Male 3128 AOR 0.8 (0.6, 0.96) CV or high risk diabetes, Canada, 
1993–5
65 [34]
Female versus Male 494 AOR 1.3 (0.8, 2.3) SY, MSM, IDU, Vancouver, 1998 32 ± 11 [25]
Female versus Male 4158 URR 1.0 (0.9. 1.1) 
[p = 0.30]*
9 population comparisons 
from 5 studies
(8–65+) [31,35,41,49,54]
Urban versus Rural 647 URR 1.3 (1.2, 1.5) 
[p = 0.59]*
3 population comparisons 
from 2 studies
(16–76) [41,46]
Born in high risk country versus 
born in Canada
494 AOR 2.9 (1.1, 7.6) SY, MSM, IDU, Vancouver, 1998 32 ± 11 [25]
Born in endemic country versus 
born in Canada
1003 AOR 22.3 (6.6, 75.0) School-aged children, Canada, 
2003
(8–13) [48]
Foreign-born versus Canadian-born 353 AOR 6.2 (2.6, 15.0) Gay men, Montreal, 1995–97 36 [28]
Born in a high-income country 
versus moderate to low†
492 AOR 20.8 (9.4, 46.0) Day-care educators, Montreal, 
2001
37 [23]
Foreign-born versus Canadian-
born
3008 URR 5.7 (3.6, 9.0) 
[p < 0.01]*
5 population comparisons 
from 5 studies
(2–69+) [30,31,49,51,53]
TRAVEL TO HIGH RISK 
AREA
Travel to high risk area versus 
otherwise
1003 AOR 1.4 (0.4, 4.8) School-aged children, Canada, 
2003
(8–13) [48]
Travel to high risk areas versus 
otherwise
407 URR 2.8 (1.4, 5.5) Canadian-born adults, Vancouver, 
2003
(20–39) [49]
Ever travelled to a developing 
country‡
492 AOR 2.4 (1.3, 4.2) Day-care educators, Montreal, 
2001
37 [23]
HIGH RISK ACTIVITIES
MSM versus heterosexuals 494 AOR 2.4 (0.9, 6.1) SY, MSM, IDU, Vancouver, 1998 (25–34) [25]
Sexual partners with VH history 
versus otherwise
420 AOR 13.8 (4.2, 45.2) Street youths, Montreal, 1995–6 (14–25) [30]
Insertive anal penetration versus 
otherwise
420 AOR 5.1 (1.6, 16.7) Street youths, Montreal, 1995–6 (14–25) [30]
History of STD versus no history 500 AOR 2.0 (1.2, 3.3) Street people, Winnipeg, 1995–6 26 (11–65) [29]
History of IDU versus no history 494 AOR 6.5 (1.6, 26.3) SY, MSM, IDU, Vancouver, 1998 (25–34) [25]
History of IDU versus no history 500 AOR 1.6 (0.99, 2.7) Street people, Winnipeg, 1995–6 26 (11–65) [29]
FIRST NATIONS AND INUIT
Native versus Non-native 1003 AOR 5.2 (1.0, 26.0) School-aged children, Canada, 
2003
(8–13) [48]
Aboriginal versus Non-aboriginal 500 AOR 6.6 (3.8, 11.5) Street people, Winnipeg, 1995–6 26 (11–65) [29]
Inuit versus white in NWT 708 URR 4.5 (2.4, 8.5) Inuits, Baker Lake, NWT, 1980 (0.3–86) [39,40]
4+ versus 1–3 household occupants 635 URR 1.1 (0.98, 1.3) Canadian Inuit, Baker Lake, 1980 (0.3–86) [39,40]
OTHERS
Years working in day-care, 5-year 
groups§
339 AOR 1.3 (1.0, 1.8) Canadian-born day-care 
educators, Montreal, 2001
34 [23]
History of daycare versus no 
history
1278 URR 1.2 [0.7, 2.2] 
[p = 0.30]*
2 population comparisons 
from 2 studies
8–13 [31,48]BMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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not associated with seropositivity [31]. Also, the seropos-
itivity was 1.3–1.6 times higher in children aged 8–13
who attended day-care, but no statistical difference was
evident in all participants, non-vaccinated participants, or
those without known risk factors [48].
Other potential risk factors were also examined. From a
sample of 343 individuals who tested positive for hepati-
tis C, 30% of those aged 20–29 were seropositive for HAV
[27]. One prospective cohort followed 62 household con-
tacts and 20 index cases over 6 months; the risk of infec-
tion was 52% among other susceptible household
members [43]. Working in a sewage plant was not associ-
ated with seropositivity [33].
Discussion
The seroprevalence data consolidated in this systematic
review had many limitations. Except for one national sur-
vey in ages 8–13 [48], other studies were generally not
representative of the general population. Substantial vari-
ation across studies was observed with respect to study
population, timing, sample size, and location. Reporting
of data was inconsistent with respect to age stratification
and definition of risk factors. Some studies conducted
after the introduction of the vaccine around 1997 did not
take vaccine-induced HAV antibody into account. This
was, however, rectified in more recent studies [23,48,49].
For example, the seroprevalence in a national survey of
children aged 8–13 was 2.7% overall and 2.0% after the
exclusion of self-reported vaccinees [48]. The correspond-
ing figures in a survey of young adults aged 20–39 were
22% and 16%, respectively [49]. Given these limitations,
improvements in the reporting of future HAV prevalence
studies are required. Most importantly, prevalence data
should be stratified by participants' birthplace and
account for vaccine-induced antibody.
Results from the current systematic review show that dis-
ease acquisition occurs in adulthood rather than child-
hood [14]. In Canada, the increase in prevalence in young
adults coincides with disease importation and increasing
frequency of behavioral risk factors, such as risk activities
among MSM and street-involved populations. Even in this
low endemicity country, approximately 1 in 10 Canadians
had been infected by ages 24–29.
A low level of HAV immunity in Canada is evident from
this systematic review. Over 90% of Canadian-born indi-
viduals aged 20–29, and over 80% of those aged 30–39
remained unprotected. Canadians born outside the coun-
try generally have a higher prevalence of HAV antibody,
yet including these individuals did not significantly
improve the percentage of protected Canadians. This low
level of immunity and persistent risk of exposure to HAV
suggest that outbreaks are possible in the future [14,47].
For example, unprotected clients exposed to an infected
food handler led to mass immunizations in the early
2000's (Toronto 2002 [56], n = 19,208; London 2002
[57], n = 16,320; Vancouver 2002 [58] n = 6,000).
Clarifications are required to better understand the epide-
miology of HAV in Canada, especially the inter-relation
between timely case-notification data, seroprevalence
data, and risk factor data. In a study examining national
case-notification data from 1990–1999, estimated inci-
dence of reported cases decreased while the average age of
exposure and subsequent infection increased [12]. Given
the low seroprevalence in Canadian youth, the current
Sewer workers versus controls|| 228 URR 1.1 (0.8, 1.4) Sewer workers, Quebec City, 
1993
41 (28–64) [33]
3+ versus 0–3 siblings 502 URR 2.0 (1.7, 2.5) Travel clinic, Edmonton, 1991–2 (16–60+) [54]
Current household income 
<20,000/yr¶
153 AOR 5.3 (1.2, 24.2) Foreign-born day-care educators, 
Montreal, 2001
39.7 [23]
Annual family income <30,000 vs 
≥ 30,000
1057 URR 0.7 (0.3, 2.0) School-aged children, Canada, 
2003
(8–13) [48]
Abbreviations: AOR adjusted odds ratio. CV cardiovascular. SY street youth. MSM men who have sex with men. IDU injectable drug user. URR 
unadjusted relative risk. STD sexually transmitted disease. NWT North West Territory. G6 grade 6. yr year
Notes: *Meta-analytical estimates (95% CI) [p-value from a test of homogeneity] from random-effects models. † The day-care educator study 
included 492 participants, including 339 Canadian-born individuals and 153 foreign-born. The odds-ratio for "born in a high-income country versus 
moderate to low" was 20.8 (95% CI 9.4, 46.0) for all 492 participants, not reported for Canadian-born, and 4.6 (1.7, 12.2) for foreign-born. ‡ The 
odds-ratio for "ever traveled to a developing country" in the day-care educators study was 2.4 (1.3, 4.2) for all 492 participants, not significant for 
Canadian-born (estimated OR not available), and 8.1 (2.3, 29.0) for foreign-born. § The odds-ratio for "years working in day-care, 5-year groups" 
was not significant for all 492 participants (estimated OR not available), 1.3 (1.0, 1.8) for Canadian-born, and not significant (estimated OR not 
available) for foreign-born. || Control subjects were outpatients undergoing lipid testing,. ¶ The odds-ratio for "current household income <20,000/
yr" in the day-care educators study was not significant (estimated OR not available) for all 492 participants and Canadian-born and was 5.3 (1.2, 
24.2) for foreign-born.
Table 3: Assessment of risk factors (Continued)BMC Infectious Diseases 2005, 5:56 http://www.biomedcentral.com/1471-2334/5/56
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results suggest that the average age of HA exposure is
above 24 and is increasing. While infection in children is
often sub-clinical or mild, infected adults often experience
more severe symptoms [1,59].
Results of the current systematic review are consistent
with low HAV endemicity patterns in developed countries
[60-62]. A substantial burden of infection was observed in
young Canadians and this did not decrease among succes-
sive generations over the past 20 years. Similar observa-
tions were reported elsewhere [63]. In these low
endemicity countries, outbreaks are common [64,65].
Sources of outbreaks that are common in these countries
include infected food handlers [56,57], contaminated
food importation [66,67], and unprotected immigrants
who visit friends and relatives in their original countries
[68].
In order to apply the current immunization recommenda-
tions, substantial information pertaining to groups at
increased risk of HA infection or its complications is
required. Results from this systematic review suggest that
the risk of HA infection in these target groups was not well
documented. With the exception of a few population-
based surveys [48,49], most studies enrolled participants
with known risk factors and failed to include a control
group. In addition, some used residual sera obtained for
other tests with virtually no risk factor data.
Conclusion
Results from the current systematic review show that in
this low endemicity country, disease acquisition occurs in
adulthood rather than childhood. The burden of disease
is high; approximately 1 in 10 Canadians had been
infected by ages 24–29. The increase in prevalence in
young adults coincides with disease importation and
increasing frequency of risk factors, most likely behavio-
ral-related ones.
Gaps in seroprevalence data were also identified in this
systematic review, rendering the application of current
recommendations difficult. A nationwide prevalence sur-
vey for all Canadians is needed. This is essential to quan-
tify the effectiveness of current recommendations [10]
and conduct cost-effectiveness evaluations of alternative
immunization programs, if necessary [69].
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